LTR Pharma Completes Phase II Recruitment for SPONTAN, Data Due Q2 2026
LTR Pharma has finalised recruitment for its Phase II clinical trial of SPONTAN, a rapid-acting intranasal spray for erectile dysfunction, with initial results expected in the second quarter of 2026.
- Phase II recruitment completed with 27 participants across three cohorts
- Dedicated cohort of participants aged 65 and older included
- Study follows FDA Pre-IND guidance and supports 505(b)(2) regulatory pathway
- Dosing underway with single and multiple doses over a 15-day residential period
- Initial pharmacokinetic data expected in Q2 2026
Clinical Milestone Achieved
LTR Pharma Limited (ASX:LTP) has announced the successful completion of recruitment for its Phase II pharmacokinetic clinical study of SPONTAN, its innovative rapid-acting intranasal spray designed to treat erectile dysfunction (ED). The study enrolled 27 participants divided into three cohorts, with the final group currently undergoing dosing at a clinical research facility.
This milestone marks a significant step forward in LTR Pharma’s clinical development program, aligning with the company’s strategy to advance SPONTAN through the US Food and Drug Administration’s (FDA) 505(b)(2) regulatory pathway. The study design follows FDA Pre-Investigational New Drug (Pre-IND) guidance, underscoring the company’s disciplined approach to regulatory compliance.
Focus on Older Demographics
Notably, the trial includes a dedicated cohort of participants aged 65 years and older, a demographic often underserved by oral ED therapies. This group represents approximately half of the study population, reflecting the company’s commitment to generating relevant pharmacokinetic data that could inform dose optimisation and labelling for older patients in future US regulatory submissions.
Given that oral PDE5 inhibitors typically require dose adjustments in older men due to increased systemic exposure, this focused approach may provide LTR Pharma with a competitive edge in tailoring SPONTAN’s use for a key patient segment.
Advancing Through the Clinical Pipeline
The Phase II study builds on earlier Phase I results, which demonstrated that SPONTAN achieves absorption up to five times faster than traditional oral tablets. Participants are currently undergoing a 15-day residential dosing period, receiving both single and multiple doses of SPONTAN alongside a control vardenafil tablet, allowing for robust comparative pharmacokinetic analysis.
Executive Chairman Lee Rodne highlighted the company’s steady progress, stating that completing recruitment on schedule reflects disciplined execution. He reaffirmed the company’s confidence in delivering initial data in the second quarter of 2026, a key event that investors and stakeholders will watch closely.
Broader Pipeline and Market Potential
Beyond SPONTAN, LTR Pharma is expanding its intranasal drug-delivery platform with other products such as ROXUS, another fast-acting ED treatment, and OROFLOW, targeting oesophageal motility disorders. These developments position the company well to address unmet medical needs with patient-centric therapies that offer rapid onset and convenience.
As LTR Pharma advances its clinical programs and regulatory engagements, the upcoming Phase II data release will be pivotal in shaping the company’s US market entry strategy and broader commercial prospects.
Bottom Line?
With Phase II recruitment complete, all eyes turn to Q2 2026 for SPONTAN’s pivotal pharmacokinetic data.
Questions in the middle?
- How will the Phase II pharmacokinetic data influence SPONTAN’s dosing recommendations for older patients?
- What are the potential timelines and hurdles for FDA approval following this study?
- How might SPONTAN’s rapid absorption impact its competitive positioning against existing ED therapies?
